Anchorage Capital Group’s Ginkgo Bioworks DNA Stock Holding History

Anchorage Capital Group’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.3M	Hold	1,746,363	–	–	3.84%	3
2026 Q1	$10.7M	Hold	1,746,363	–	–	2.45%	3
2025 Q4	$14.5M	Hold	1,746,363	–	–	16.39%	2
2025 Q3	$25.5M	Hold	1,746,363	–	–	21.69%	2
2025 Q2	$19.6M	Hold	1,746,363	–	–	7.59%	4
2025 Q1	$9.95M	Hold	1,746,363	–	–	3.98%	5
2024 Q4	$17.1M	Hold	1,746,363	–	–	6.03%	4
2024 Q3	$14.2M	Sell	1,746,363 -2	-0%	-$20	3.73%	4
2024 Q2	$23.4M	Hold	1,746,365	–	–	7.21%	4
2024 Q1	$81M	Hold	1,746,365	–	–	21.09%	3
2023 Q4	$118M	Hold	1,746,365	–	–	14.05%	3
2023 Q3	$126M	Hold	1,746,365	–	–	11.43%	3
2023 Q2	$130M	Hold	1,746,365	–	–	11.46%	3
2023 Q1	$92.9M	Hold	1,746,365	–	–	14.36%	3
2022 Q4	$118M	Buy	1,746,365 +17,406	+1%	+$1.6M	15.14%	3
2022 Q3	$216M	Hold	1,728,959	–	–	19.25%	2
2022 Q2	$165M	Hold	1,728,959	–	–	16.46%	2
2022 Q1	$279M	Hold	1,728,959	–	–	18.94%	2
2021 Q4	$575M	Buy	1,728,959 +50,175	+3%	+$23.8M	23.78%	1
2021 Q3	$778M	Buy	+1,678,784	New	+$817M	20.15%	2

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Anchorage Capital Group's DNA Position: Q2 2026 in Review

Anchorage Capital Group held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 1,746,363 shares worth $17.3M. The position accounts for 3.84% of the portfolio, ranked #3.

Anchorage Capital Group first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $778M in Q3 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Anchorage Capital Group held 1,746,363 shares of Ginkgo Bioworks worth $17.3M as of Q2 2026.
Anchorage Capital Group left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 3.84% of Anchorage Capital Group's portfolio in Q2 2026, its #3 holding.
Anchorage Capital Group first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
Anchorage Capital Group's Ginkgo Bioworks position peaked at $778M in Q3 2021.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Anchorage Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.